Comparing Safety and Adequacy Between Surgical Biopsy Versus Core Needle Biopsy in Diagnosing Neuroblastoma

2022 ◽  
Author(s):  
Hisham Mohamed ◽  
M. Chris Pastor ◽  
Stéphanie Langlois ◽  
Kyle N. Cowan
Keyword(s):  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Surgical Biopsy ◽  
Core Needle

scholarly journals Percutaneous Core Needle Biopsy Can Efficiently and Safely Diagnose Most Primary Bone Tumors

Diagnostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1552
Author(s):  
Vincent Crenn ◽  
Léonard Vezole ◽  
Amine Bouhamama ◽  
Alexandra Meurgey ◽  
Marie Karanian ◽  
...  
Keyword(s):  
Complication Rate ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Bone Tumors ◽  
First Line ◽  
Surgical Biopsy ◽  
Core Needle ◽  
Reference Center ◽  
Referral Center ◽  
Percutaneous Core Needle Biopsy

A biopsy is a prerequisite for the diagnosis and evaluation of musculoskeletal tumors. It is considered that surgical biopsy provides a more reliable diagnosis because it can obtain more tumor material for pathological analysis. However, it is often associated with a significant complication rate. Imaging-guided percutaneous core needle biopsy (PCNB) is now widely used as an alternative to surgical biopsy; it appears to be minimally invasive, possibly with lower complication rates. This study evaluates the diagnostic yield of the preferred use of PCNB in a referral center, its accuracy, and its complication rate. The data relating to the biopsy and the histological analysis were extracted from the database of a bone tumor reference center where PCNB of bone tumors was discussed as a first-line option. 196 bone tumors were biopsied percutaneously between 2016 and 2020. They were located in the axial skeleton in 21.4% (42) of cases, in the lower limb in 58.7% (115), and in the upper limb in 19.9% (39) cases. We obtained a diagnosis yield of 84.7% and a diagnosis accuracy of 91.7%. The overall complication rate of the percutaneous biopsies observed was 1.0% (n = 2), consisting of two hematomas. PCNB performed in a referral center is a safe, precise procedure, with a very low complication rate, and which avoids the need for first-line open surgical biopsy. The consultation between pathologist, radiologist, and clinician in an expert reference center makes this technique an effective choice as a first-line diagnosis tool.

Does 8-guage stereotactic core needle biopsy improve the accuracy over 11-gauge devices? Evaluation of pure DCIS on stereotactic biopsy and the rate of upstaging.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 97-97
Author(s):  
Deepa R. Halaharvi ◽  
Mark H. Cripe
Keyword(s):  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Stereotactic Biopsy ◽  
Ductal Carcinoma ◽  
P Value ◽  
Breast Cancers ◽  
Surgical Biopsy ◽  
Core Needle ◽  
Stereotactic Core Needle Biopsy ◽  
Stereotactic Core

97 Background: Ductal carcinoma in situ (DCIS) accounts for 25% of newly diagnosed breast cancers. Core needle biopsy (CNB) has replaced open surgical biopsy for mammographic calcifications. We compare our experience with 8-gauge vs. 11-gauge vacuum assisted core needle biopsy in pure DCIS. We hypothesize that the diagnosis of DCIS with use of an 8-gauge vacuum-assisted core needle will lead to a lower rate of upstaging to invasive cancer at definitive surgical excision compared to 11-gauge vacuum-assisted core needle biopsy. Methods: A retrospective study was performed evaluating all patients who underwent a stereotactic core needle biopsy at our institution for DCIS during 2008-2012.We then compared the upstaging rates between patients biopsied using 8 or 11-gauge biopsy devices. Results: A total of 580 patients underwent STCNB during 2008-2012 at our institution, there were 461 patients excluded as they did not meet inclusion criteria and 119 patients were included. The most common mammographic finding was calcifications in 104/119 (87.4%) and a mammographic mass in 15/119 (12.60%). Biopsy with the 11 gauge needle was utilized in 60 patients and 59 patients with 8-G needle. Factors associated with upstaging were using a smaller 11 gauge needle and a mass on imaging, higher grade and more than four cores obtained on biopsy. There was an upstaging rate of 17/60 (28%) in patients who underwent stereotactic biopsy using a11-gauge needle versus upstaging rate of 7/59 (11.8%) in patients who underwent stereotactic biopsy using 8 gauge needle. We obtained a statistically significant p-value of 0.025. Conclusions: This is one of the few studies comparing upstaging rates from pure DCIS on STCNB using 8 and 11-gauge stereotactic vacuum assisted needles. Our results show that there is a statistically significant decrease in upstaging of pure DCIS to invasive malignancy at excision using the larger 8-gauge needle devices. The clinical implication is that SLNB need not be performed secondary to the low upstaging rate. We recommend that all stereotactic core needle biopsies be performed using the 8-gauge needle devices, and that SLNB generally be omitted for DCIS.

Image-guided core-needle biopsy in malignant lymphoma: experience with 100 patients that suggests the technique is reliable.

1996 ◽  
Vol 14 (9) ◽  
pp. 2431-2434 ◽  
Author(s):  
D Ben-Yehuda ◽  
A Polliack ◽  
E Okon ◽  
Y Sherman ◽  
S Fields ◽  
...  
Keyword(s):  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Diagnostic Procedure ◽  
Sufficient Information ◽  
Surgical Biopsy ◽  
Ct Guided ◽  
Biopsy Needle ◽  
Core Needle ◽  
Image Guided ◽  
Primary Location

PURPOSE In an initial evaluation of 1,500 computed tomography (CT)-guided core-needle biopsies performed at our institute during the period from 1989 to 1994, we encountered 100 patients with the diagnosis of lymphoma. Here, we review the clinical impact of 109 image-guided needle biopsies in these 100 patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). PATIENTS AND METHODS NHL was diagnosed in 71 patients, and 29 had HD. Among the NHL patients, 17 (24%) had proven lymphoma diagnosed before the biopsy was performed; in 54 (76%) core-needle biopsy was performed as the first diagnostic procedure. Of 29 HD patients, nine (31%) were already established cases of HD, and in 20 (69%) core-needle biopsy was the first diagnostic procedure attempted. Most of the biopsies were performed under CT control using a 20- or 18-gauge Turner biopsy needle. RESULTS Eighty-six patients received therapy based on the results of the needle biopsy alone. Fourteen patients received therapy after undergoing surgical biopsy for a suspected diagnosis of lymphoma, which could not be established with certainty on the basis of an earlier core-needle biopsy alone. In 78% of the patients, the needle biopsy saved a further surgical procedure that may have been difficult to perform because of the primary location of the tumor. CONCLUSION From our experience in this study, image-guided core-needle biopsies provide sufficient information for the diagnosis of and subsequent therapeutic decision to treat most cases of lymphoma.

Obturator-Assisted Prolapse for Access to and Sampling of Colorectal Masses in Seven Dogs

2020 ◽  
Vol 56 (3) ◽  
Author(s):  
Ewan Wolff ◽  
Laura Van Vertloo ◽  
S. Kathleen Salisbury ◽  
Michael O. Childress
Keyword(s):  
Treatment Planning ◽  
Core Needle Biopsy ◽  
Gold Standard ◽  
Needle Biopsy ◽  
Physical Exam ◽  
Surgical Biopsy ◽  
Core Needle ◽  
Computed Tomographic ◽  
Major Complications ◽  
Histopathologic Diagnosis

ABSTRACT The gold standard for diagnosis of colorectal masses is surgical biopsy; however, this is not always logistically or economically feasible. The authors present an alternative to established flexible and rigid endoscopic approaches when case limitations require such an approach. In seven dogs, after the identification of a mass on physical exam and computed tomographic evaluation, the colorectum was accessed using obturator-assisted prolapse to isolate discrete masses and perform shielded sampling via core needle biopsy. Histopathologic diagnosis was adequate for treatment planning in all dogs. No major complications were recorded 65–475 days after the procedure. This technique may be useful when traditional endoscopy and surgery for biopsy of colorectal masses is unavailable.

A systematic review of surgical biopsy for LCIS found at core needle biopsy – Do we have the answer yet?

2014 ◽  
Vol 40 (2) ◽  
pp. 168-175 ◽  
Author(s):  
E.S. Buckley ◽  
F. Webster ◽  
J.E. Hiller ◽  
D.M. Roder ◽  
G. Farshid
Keyword(s):  
Systematic Review ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Surgical Biopsy ◽  
Core Needle

Diagnostic accuracy of core needle biopsy by image guidance and vacuum assistance.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12081-e12081
Author(s):  
Firas M Dabbous ◽  
Sarah M. Friedewald ◽  
Ellen O'Meara ◽  
Donald L. Weaver ◽  
Karen Wernli ◽  
...  
Keyword(s):  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Ductal Carcinoma ◽  
Imaging Study ◽  
High Sensitivity ◽  
Cancer Registries ◽  
Screening Mammography ◽  
Cancer Surveillance ◽  
Surgical Biopsy ◽  
Core Needle

e12081 Background: Half of the women in the US undergoing annual screening mammography over 10 years require at least one additional imaging study. Of these women, 7%-17% undergo biopsies, the majority of which (77%) are benign. We sought to estimate the accuracy of core needle biopsy (CNB) by method of imaging guidance and use of vacuum assistance (VA). Methods: Data were pooled from four registries participating in the Breast Cancer Surveillance Consortium (bcsc-research.org) including facilities that perform both VA and non-VA CNB. Each registry collects data on screening mammography and breast pathology reports linked to their state cancer registries or regional Surveillance, Epidemiology and End Results registry. Sensitivity was defined as the proportion of positive biopsies among all cancers diagnosed within 12 months of biopsy. PPV3 was defined as the percentage of all biopsies performed that were positive for cancer. We estimated the adjusted average population risks/rates by modality using marginal standardization with logistic regression in STATA.Results: : Among the 37,270 CNBs, breast malignancy was found in 9,241 women (28.6%), of which 2,276 (25%) were ductal carcinoma in-situ. Sensitivity was 90.5% (95% CI 82.6-98.4) for non-VA Stereotactic (n = 415), 95.4% (95% CI 94.7-96.1) for VA Stereotactic (n = 18,733), 96.1% (95% CI 95.4-96.7) for non-VA ultrasound (n = 14,803), 95.1% (95% CI 93.7-96.5) for VA Ultrasound (n = 3,271) and 82.3% (95% CI 59.9-104.6) for non-VA MRI (n = 48). PPV3 was 12.2% (95% CI 9.0, 15.3), 17.7% (95% CI 17.2, 18.3), 28.6% (95% CI 27.8-29.4), 32.1% (95% CI 30.4-33.8) and 16.9% (95% CI 5.3, 28.5), respectively. For stereotactic biopsies, VA was associated with improved PPV3 (p = 0.01) without any change in sensitivity compared to non-VA Stereotactic biopsies.Conclusions: Our multicenter data confirm that VA-stereotactic CNB and ultrasound CNB with or without VA have high sensitivity and thus represent effective alternatives to open surgical biopsy.

Sign in / Sign up

Export Citation Format

Share Document